Safety and efficacy of a new supplementation protocol in patients with cystic fibrosis and vitamin D deficiency.
An Pediatr (Engl Ed)
; 98(4): 257-266, 2023 Apr.
Article
in En
| MEDLINE
| ID: mdl-36932016
ABSTRACT
OBJECTIVES:
Based on the European and American Cystic Fibrosis (CF) consensus recommendations, an increase in vitamin D (VD) supplementation in patients with CF and insufficient or defficient levels was proposed. The objective of our study was to determine the safety and efficacy of this new protocol. MATERIAL ANDMETHODS:
Multicentre nonrandomized uncontrolled experimental study. Patients with insufficient levels (<30â¯ng/mL) received increasing doses of VD (between 800 and 10 000 IU/day). Patients were followed up for 12 months, during which their vitamin and nutritional status, pulmonary function and calcium and phosphate metabolism were assessed. STATISTICALANALYSIS:
t test for paired data and multivariate logistic regression analysis.RESULTS:
Thirty patients aged 1-39 years (median, 9.1) completed the follow-up. Two patients were dropped from the study on account of 25-OH VD levels greater than 100â¯ng/mL at 3 months without clinical or laboratory signs of hypercalcaemia. At 12 months, we observed an increase of 7.6â¯ng/mL (95% CI, 4.6-10â¯ng/mL) in the mean 25-OH VD level and an improvement in vitamin status 37% achieved levels of 30â¯ng/mL or greater, 50% levels between 20 and 30â¯ng/mL and 13% remained with levels of less than 20â¯ng/mL. We found no association between improved VD levels and pulmonary function.CONCLUSIONS:
The proposed protocol achieved an increase in serum VD levels and a decrease in the percentage of patients with VD insufficiency, although it was still far from reaching the percentages of sufficiency recommended for this entity.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vitamin D Deficiency
/
Cystic Fibrosis
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
An Pediatr (Engl Ed)
Year:
2023
Document type:
Article